Accuray (NASDAQ:ARAY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday.
Accuray Stock Performance
ARAY stock opened at $1.32 on Monday. The stock’s fifty day moving average is $1.67 and its two-hundred day moving average is $1.92. The stock has a market capitalization of $135.22 million, a price-to-earnings ratio of -26.30 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. Accuray has a 1 year low of $1.28 and a 1 year high of $2.95.
Accuray (NASDAQ:ARAY – Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The firm had revenue of $113.24 million during the quarter, compared to analyst estimates of $101.53 million. On average, research analysts predict that Accuray will post 0.01 EPS for the current year.
Institutional Inflows and Outflows
Accuray Company Profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Read More
- Five stocks we like better than Accuray
- What is a Dividend King?
- 3 Mid-Cap Medical Stocks Outperforming the Market
- What Are Dividend Champions? How to Invest in the Champions
- The Top-Ranked Insider Buys From April by Market Cap
- Which Wall Street Analysts are the Most Accurate?
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.